Integrated Biopharma OTC Stock Executives

Integrated Biopharma Management Team Effectiveness

The company has return on total asset (ROA) of 0.0336 % which means that it generated a profit of $0.0336 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1268 %, meaning that it created $0.1268 on every $100 dollars invested by stockholders. Integrated Biopharma's management efficiency ratios could be used to measure how well Integrated Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Integrated Biopharma has a total of 29.95 Million outstanding shares. Integrated Biopharma retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 68.58 (percent) of Integrated Biopharma outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Integrated Biopharma Workforce Comparison

The company has Profit Margin (PM) of 0.04 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.03 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.03.

Integrated Biopharma Benchmark Summation

Integrated Biopharma Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Integrated Biopharma often depends on how effective the management is. Integrated Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Integrated management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Integrated management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

The data published in Integrated Biopharma's official financial statements typically reflect Integrated Biopharma's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Integrated Biopharma's quantitative information. For example, before you start analyzing numbers published by Integrated accountants, it's essential to understand Integrated Biopharma's liquidity, profitability, and earnings quality within the context of the Personal Products space in which it operates.

When running Integrated Biopharma's price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.